Current and Future Biomarker Testing Landscape in Alzheimer’s Disease скачать в хорошем качестве

Current and Future Biomarker Testing Landscape in Alzheimer’s Disease

In this session, Leslie Shaw, Ph.D., University of Pennsylvania, discusses how the availability of Alzheimer's biomarkers in CSF and blood is revolutionizing the diagnostic path. Early detection of Alzheimer’s disease (AD) pathology can occur in vivo using fluid biomarkers and/or Positron emission tomography (PET) imaging. The FDA approved/cleared cerebrospinal fluid (CSF) ratios can detect AD amyloid pathology early in the disease and correlate with amyloid PET. With the availability of amyloid removal therapies, which slow down cognitive decline, it is expected that laboratories will be faced with increased requests for AD testing. Discover more about Roche's commitment to Alzheimer’s Disease at https://go.roche.com/adlm2024-idealab.... Chapters: 0:00-6:31 - Lifestyle changes that may slow down progress of AD 6:31-10:40 - Diagnostic tools and biomarker testing that are FDA approved to aid in the diagnosis of AD 10:40-11:59 - The quality and reliability of CSF biomarkers 12:05-22:35 - The development of blood based biomarkers, including pTau 217 22:36-25:43 - Where blood-based biomarker best fit into the patient pathway 26:05-29:12 - How pTau 217 could be utilized MC-US-15676